Loading...
•
Mar 31, 2022
Recursion Pharmaceuticals Q1 2022 Earnings Report
Recursion Pharmaceuticals reported first quarter 2022 financial results and provided business updates.
Key Takeaways
Recursion Pharmaceuticals reported a net loss of $56.0 million for the first quarter of 2022, with total revenue of $5.3 million. The company highlighted progress in its clinical programs, including the enrollment of the first participant in a Phase 2 clinical trial for CCM and advancements in preclinical and discovery programs.
Enrolled the first participant in Phase 2 clinical trial for CCM and dosed multiple participants.
Expecting to enroll the first participant in Phase 2/3 clinical trial for progressive NF2-mutated meningiomas in the second quarter 2022.
Received Fast Track Designation for REC-4881, a potential treatment for FAP, and expect to enroll the first participant in a Phase 2 trial in the third quarter 2022.
Initiated laboratory efforts and are scaling pilot work to create first partnership-specific maps in an oncology indication with Roche and Genentech.
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Recursion Pharmaceuticals Revenue by Segment
Revenue by Segment
Collaborative agreements Revenue
CapyFin.com Forward Guidance
Recursion plans to initiate additional clinical trials later in the year and believes its work and partnerships have the potential to positively impact the lives of patients.